Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 2

Status

Completed 17Terminated 5Active not recruiting 5Recruiting 4Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 4

Conditions

Breast Neoplasms 412Carcinoma, Non-Small-Cell Lung 285Prostatic Neoplasms 208Neoplasms 202Neoplasm Metastasis 179Melanoma 164Multiple Myeloma 158Colorectal Neoplasms 157Leukemia, Myeloid, Acute 143Lung Neoplasms 132Leukemia 126Lymphoma 118Pancreatic Neoplasms 117Recurrence 111Ovarian Neoplasms 111Leukemia, Lymphocytic, Chronic, B-Cell 110Lymphoma, Non-Hodgkin 104Carcinoma, Renal Cell 104Brain Neoplasms 89Myelodysplastic Syndromes 88Precursor Cell Lymphoblastic Leukemia-Lymphoma 86Glioblastoma 84Lymphoma, Large B-Cell, Diffuse 80Lymphoma, Follicular 79Carcinoma, Hepatocellular 79Head and Neck Neoplasms 77Squamous Cell Carcinoma of Head and Neck 76Urinary Bladder Neoplasms 66Stomach Neoplasms 61Hodgkin Disease 59

Interventions

rucaparib 1Standard of Care 1Gemcitabine 1Crizotinib 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Ureteral Neoplasms × Clear all
NCT02122172 2025-04-25

Afatinib in Advanced Refractory Urothelial Cancer

University of Chicago

Phase 2 Terminated
32 enrolled 14 charts
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT04398368 2023-08-08

Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study

Mayo Clinic

Phase 2 Terminated
25 enrolled 12 charts

Ureteral Neoplasms

NCT03397394 2023-06-09

ATLAS

pharmaand GmbH

Phase 2 Terminated
97 enrolled 12 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT02612194 2022-11-03

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

Wake Forest University Health Sciences

Phase 2 Terminated
8 enrolled 16 charts
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT01353222 2017-05-25

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Dendreon

Phase 2 Terminated
142 enrolled 13 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡